0 60

Cited 0 times in

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Authors
 Robert Coleman  ;  Dianne M Finkelstein  ;  Carlos Barrios  ;  Miguel Martin  ;  Hiroji Iwata  ;  Roberto Hegg  ;  John Glaspy  ;  Alvaro Montaño Periañez  ;  Katia Tonkin  ;  Ines Deleu  ;  Joohyuk Sohn  ;  John Crown  ;  Suzette Delaloge  ;  Tian Dai  ;  Ying Zhou  ;  Danielle Jandial  ;  Arlene Chan 
Citation
 LANCET ONCOLOGY, Vol.21(1) : 60-72, 2020-01 
Journal Title
LANCET ONCOLOGY
ISSN
 1470-2045 
Issue Date
2020-01
MeSH
Adult ; Biomarkers, Tumor / metabolism ; Bone Density Conservation Agents / therapeutic use* ; Bone Neoplasms / drug therapy* ; Bone Neoplasms / metabolism ; Bone Neoplasms / secondary ; Breast Neoplasms / drug therapy* ; Breast Neoplasms / metabolism ; Breast Neoplasms / pathology ; Chemotherapy, Adjuvant / mortality* ; Denosumab / therapeutic use* ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoadjuvant Therapy / mortality* ; Neoplasm Recurrence, Local / drug therapy* ; Neoplasm Recurrence, Local / metabolism ; Neoplasm Recurrence, Local / pathology ; Neoplasm Staging ; Receptor, ErbB-2 / metabolism ; Receptors, Estrogen / metabolism ; Receptors, Progesterone / metabolism ; Survival Rate
Abstract
Background Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments would increase bone metastasis-free survival in women with breast cancer. Method In this international, double-blind, randomised, placebo-controlled, phase 3 study (D-CARE), patients were recruited from 389 centres in 39 countries. We enrolled women (aged >= 18 years) with histologically confirmed stage II or III breast cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1. On eligibility confirmation, investigators at each site telephoned an interactive voice response system to centrally randomly assign patients (1:1) based on a fixed stratified permuted block randomisation list (block size 4) to receive either denosumab (120 mg) or matching placebo subcutaneously every 3-4 weeks, starting with neoadjuvant or adjuvant chemotherapy, for about 6 months and then every 12 weeks for a total duration of 5 years. Stratification factors were breast cancer therapy, lymph node status, hormone receptor and HER2 status, age, and geographical region. The primary endpoint was the composite endpoint of bone metastasis-free survival. This trial is registered with ClinicalTrials.gov, NCT01077154. Findings Between June 2, 2010, and Aug 24, 2012, 4509 women were randomly assigned to receive denosumab (n=2256) or placebo (n=2253) and included in the intention-to-treat analysis. The primary analysis of the study was done when all patients had the opportunity to complete 5 years of follow-up with an analysis data cutoff date of Aug 31, 2017. The primary endpoint of bone metastasis-free survival was not significantly different between the groups (median not reached in either group; hazard ratio 0.97, 95% CI 0.82-1.14; p=0.70). The most common grade 3 or worse treatment-emergent adverse events, reported in patients who had at least one dose of the investigational product (2241 patients with denosumab vs 2218 patients with placebo), were neutropenia (340 [15%] vs 328 [15%]), febrile neutropenia (112 [5%] vs 142 [6%]), and leucopenia (62 [3%] vs 61 [3%]). Positively adjudicated osteonecrosis of the jaw occurred in 122 (5%) of 2241 patients treated with denosumab versus four (<1%) of 2218 patients treated with placebo; treatment-emergent hypocalcaemia occurred in 152 (7%) versus 82 (4%). Two treatment-related deaths occurred in the placebo group due to acute myeloid leukaemia and depressed level of consciousness. Interpretation Despite preclinical evidence suggesting RANKL inhibition might delay bone metastasis or disease recurrence in patients with early-stage breast cancer, in this study, denosumab did not improve disease-related outcomes for women with high-risk early breast cancer.
Full Text
https://www.sciencedirect.com/science/article/pii/S1470204519306874
DOI
10.1016/S1470-2045(19)30687-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190286
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links